LITE: An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
Study Details
Study Description
Brief Summary
The study observes real world patients with primary hypercholesterolemia who receive a fixed dose combination therapy with atorvastatin and ezetimibe for 24 weeks; collects and analyzes data related to efficacy and safety of the therapy; and evaluates efficacy and safety of the fixed dose combination therapy with atorvastatin and ezetimibe.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The prevalence of hypercholesterolemia, an atherosclerotic dyslipidemia which is the major cause of coronary artery diseases has risen. According to numerous studies, LDL-C is the key cause of atherosclerosis and it has been reported that treating patients to lower the LDL-C level will reduce the incidence of cardiovascular diseases. Currently, patients are classified into risk groups to receive a recommended therapy based on the defined criteria in Korea and Statin is the primary therapeutic agent recommended. However, there have been concerns that an increased dose of statins may result in hepatoxicity and reports that a combination therapy with ezetimibe without an additional dose of statins has clinical benefits. Ezetimibe is a drug that inhibits cholesterol absorption in the small intestine and reduces the LDL-C level. The therapeutic guideline, first of all, recommends combination therapy with ezetimibe among other drugs whose clinical benefits have been confirmed in cases where the target LDL-C level is not met with statins.
The study observes real world patients with primary hypercholesterolemia who receive a fixed dose combination therapy with atorvastatin and ezetimibe for 24 weeks; collects and analyzes data related to efficacy and safety of the therapy; and evaluates efficacy and safety of the fixed dose combination therapy with atorvastatin and ezetimibe.
During this study period, the scope of data to be collected is as follows:
-
Demographic data
-
Indication diagnosis and characteristics
-
Cardiovascular risk
-
Medical history
-
Statin medication
-
Preceding/Concomitant drug
-
Administration of fixed dose combination therapy with atorvastatin and ezetimibe
-
Collecting efficacy endpoints: Lipid profile(LDL-C, TC, TG, HDL-C, non-HDL-C)
-
Collecting safety endpoints: ADR, SAE, SADR, HbA1C, FPG, AST, ALT, CPK
Study Design
Outcome Measures
Primary Outcome Measures
- Rate of reaching the target LDL-C level [Week 24]
Rate of reaching the target LDL-C level at Week 24
Secondary Outcome Measures
- Rate of reaching the target LDL-C level [Week 12]
Rate of reaching the target LDL-C level at Week 12
- Rate of change compared to the baseline when it comes to the level of TC, TG, LDL-C, HDL-C and non-HDL-C [Week 12 and Week 24]
Rate of change at Week 12 and Week 24 compared to the baseline when it comes to the level of TC, TG, LDL-C, HDL-C and non-HDL-C
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Those who are briefed about the clinical trial objectives and methods, and express their consent to participate in the trial by signing a written consent on the use of their personal information.
-
Any male/female subjects 19 years old or older.
-
Those who will be given for the first time a fixed dose combination therapy with atorvastatin and ezetimibe to treat primary hypercholesterolemia.
-
Those with levels of total cholesterol, LDL-C, HDL-C, non-HDL-C and TG confirmed within 2 weeks prior to the registration.
-
Those who failed to reach to the target LDL-C level per risk group based on the risk group classification specified in the therapeutic guideline for dyslipidemia (2018).
[Risk Group, Target LDL-C (mg/dL) Level]
-
Very High Risk <70
-
Coronary artery disease
-
Atherosclerotic ischemic stroke and transient cerebral ischemic attack
-
Peripheral arterial disease
-
High Risk <100
-
Carotid disease (When significant carotid artery stenosis is diagnosed)
-
Abdominal aneurysm
-
Diabetes (For patients with major risk factors such as damage to target organs or cardiovascular diseases, the target level may be lowered based on the patient conditions)
-
Moderate Risk <130
-
2 or more major risk factors(May include age (45 years old for male subjects and 55 years old for female subjects), family history of initial coronary artery disease stage, hypertension, smoking, low HDL-C)
-
Low Risk <160
-
1 or less major risk factors(May include age (45 years old for male subjects and 55 years old for female subjects), family history of initial coronary artery disease stage, hypertension, smoking, low HDL-C)
- Those who fully understand the clinical trial, are cooperative throughout the trial and capable of participating in the trial until it ends.
Exclusion Criteria:
-
Those who are hypersensitive to major ingredients or other ingredients of the investigational drug.
-
Hypertriglyceridemia patients whose triglyceride level is 400mg/dL or higher under fasting conditions.
-
Patients with serious hepatopathy (whose ALT or AST level is more than twice the upper limit of normal (ULN)).
-
Patients with serious nephropathy (whose serum creatinine level is more than twice the upper limit of normal (ULN)).
-
Those who have medical history of myopathy and rhabdomyolysis.
-
Female patients who are pregnant, suspected to be pregnant or breastfeeding.
-
Those who are administrating glecaprevir and pibrentasvir.
-
The drug contains lactose, thus those who have genetic problems, including galactose intolerance, Lapp lactase deficiency and glucose-galactose malabsorption.
-
Those who are currently participating in other clinical trials (any trials with drugs or medical devices) or who have been administered with investigational drugs of other clinical trials within 4 weeks from the baseline. However, those participating in non-interventional trials or being observed after the drug administration is complete may take part in the trial.
-
Those who are currently hospitalized or are expected to be hospitalized.
-
Those who are suffering from severe or unstable medical and mental illnesses that may impact the trial as assessed by the investigators.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Severance Hospital, Yonsei University Health System | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Boryung Pharmaceutical Co., Ltd
Investigators
- Study Director: MyungSook Hong, Boryung Co.,Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BR-EAC-OS-401